BPC-157 (Body Protection Compound 157) is a stable gastric pentadecapeptide consisting of 15 amino acids, isolated from human gastric juice. It has demonstrated remarkable stability against enzymatic degradation, hydrolysis, and even gastric juice. In extensive preclinical research, BPC-157 has shown pleiotropic beneficial effects including accelerated healing of tendons, muscles, ligaments, bones, and the gastrointestinal tract. It has been in clinical trials for inflammatory bowel disease (IBD) and multiple sclerosis. Unlike many peptides, BPC-157 can be administered orally as well as by injection due to its stability in the GI tract.
< 30 minutes
Subcutaneous injection
0
1419 Da
BPC-157 works through multiple mechanisms: (1) Upregulation of VEGFR2 and promotion of angiogenesis, supporting blood vessel formation and tissue repair; (2) Interaction with the nitric oxide (NO) system; (3) Modulation of growth factors involved in wound healing; (4) Effects on the dopaminergic and serotonergic systems in the CNS; (5) Activation of the FAK-paxillin pathway in tendon healing, promoting cell migration and survival; (6) Cytoprotective and anti-inflammatory properties. BPC-157 demonstrates activity at very low doses and operates through what researchers describe as a 'brain-gut axis' connection.
Extensive animal research demonstrating healing effects across multiple tissue types. Limited human data: 2 pilot trials and 1 retrospective case series. Majority of research from Croatian group (Sikiric et al.). No large-scale human RCTs yet.
Gly-Glu-Pro-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val